Close Menu

University of Manchester

By Monica Heger
This study was originally published Feb. 7.

Epistem plans to use novel preclinical models for cutaneous wound healing developed by a University of Manchester scientist under a partnership that is supported by a UK government business development program.

ProteoMonitor spoke to Tony Whetton, Head of the School for Cancer and Enabling Sciences at the University of Manchester, about his work applying proteomics to stem cell research.

A Myconostica official said this week that the company will debut a MycArray Mold ID array by the beginning of 2012 that will be designed to identify different species of microscopic fungi.

Under the terms of the agreement, Link will manufacture and sell diagnostic reagents based on the so-called exciplex technology, which is able to reduce the background fluorescent signal in nucleic acid assays in order to improve the detection sensitivity.

The company will make and sell a Manchester-developed diagnostic reagent technology through an agreement that includes a research collaboration.

The company is looking to differentiate itself from other players in the miRNA array market — such as Agilent Technologies, Life Technologies, Exiqon, and Febit — by stressing the "quality, performance, and affordability" of its OneArray platform.

The university will use the system in its stem cell and leukemia proteomics studies.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.